A new peer-reviewed article on the Food and Drug Administration’s (FDA) 2021 complete review of mifepristone’s Risk Evaluation and Mitigation Strategy (REMS) program provisions found the agency lacked sufficient evidence to justify removal of the in-person dispensing requirement.

A new peer-reviewed study by Charlotte Lozier Institute (CLI) researchers used Medicaid data to identify a history of pregnancy loss, which includes miscarriage, stillbirth, and abortion, as risk factors for severe maternal morbidity (SMM) in future pregnancies.

A new peer-reviewed article by the Charlotte Lozier Institute (CLI) identifies informed consent gaps for abortion drugs as women report unexpected pain, bleeding, and mental health impacts

A new Charlotte Lozier Institute (CLI) report discovered many online abortion drug sellers are violating U.S. laws, exceeding FDA safety limits, and selling unapproved and misbranded drugs to U.S. consumers. This blatant disregard for the law was only boosted by the removal of the in-person dispensing requirement in 2021. The report identifies these violations across online sellers operating outside of the U.S. healthcare system as well as the violations committed by online abortion drug sellers operating within the healthcare system.

Ahead of Mother’s Day, Charlotte Lozier Institute (CLI) launched an updated version of Voyage of Life (VoL) along with a new pregnancy calculator. VoL is an interactive, educational website created by CLI that uses up-to-date, peer-reviewed research and medically grounded visuals to illustrate human development from fertilization through birth.

Today, the Supreme Court temporarily blocked the 5th U.S. Circuit Court ruling that paused the nationwide remote shipment of abortion drugs, mifepristone and misoprostol, in Louisiana v. FDA.